Advancing new potential treatments for certain GI diseases affecting millions of patients in need
Thoughtfully Approaching GI Drug Discovery
Ironwood Pharmaceuticals’ commitment to redefining the standard of care for patients suffering from GI diseases and disorders is unwavering. We understand that debilitating GI diseases exist, and countless patients need meaningful and effective medicines.
We are focused on following the science and strengthening our portfolio by pursuing opportunities in organic GI diseases with significant unmet medical need, strong mechanistic rationale, and commercial viability. By following this strategy, we can leverage our leading GI capabilities and expertise now and in the future.
Strengthening Our Leading GI Portfolio
We expanded our pipeline by entering into a collaboration and option agreement with COUR Pharmaceuticals for U.S. rights to CNP-104, a tolerizing immune modifying nanoparticle, that has the potential to transform the treatment of primary biliary cholangitis (PBC) – a rare autoimmune disease targeting the liver that affects an estimated 133,000 people in the United States. The FDA granted Fast Track Designation for CNP-104 and we expect a clinical trial for CNP-104 to begin soon with a data readout anticipated in 2023.
COUR’s proprietary platform combines PDC-E2 with state-of-the-art pharmaceutical nanoparticles to tolerize the immune system and potentially eliminate the immune bile duct destruction present in PBC, meaning CNP-104 has the opportunity to be the first PBC disease-modifying therapy on the market. As there is currently no therapy that addresses the root cause of the autoimmune destruction of the bile ducts in PBC with medical care currently focused on disease management, CNP-104 has the potential to impact the lives of patients. COUR Pharmaceuticals’ platform has shown proof of technology in clinical and preclinical settings further supporting the opportunity for the platform to treat PBC.
We are currently advancing our wholly owned IW-3300 – a stable and potent GC-C agonist – into clinical development for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis, that affect millions of patients in the U.S. Currently there are a limited number of treatment options available and high unmet need among patients experiencing these conditions.
We have strong preclinical data in several models that suggest the potential for GC-C stimulation with IW-3300 to alleviate visceral pain. We are soon to start the clinical program for IC/BPS.
As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.Partner with Us